Menu
Back to User profile » Dr Angelo Ruggiero
Papers published by Dr Angelo Ruggiero:
The Past, the Present and the Future of Teledermatology: A Narrative Review
Tommasino N, Megna M, Cacciapuoti S, Villani A, Martora F, Ruggiero A, Genco L, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:717-723
Published Date: 21 March 2024
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:463-464
Published Date: 24 February 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:51-57
Published Date: 8 January 2024
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
Megna M, Ruggiero A, Salsano A, Lauletta G, Portarapillo A, Torta G, Martora F, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3503-3507
Published Date: 5 December 2023
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
Ruggiero A, Portarapillo A, Megna M, Patruno C, Napolitano M
Pediatric Health, Medicine and Therapeutics 2023, 14:435-451
Published Date: 14 November 2023
JAK Inhibitors in Psoriatic Disease
Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3129-3145
Published Date: 31 October 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2637-2644
Published Date: 25 September 2023
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2525-2536
Published Date: 18 September 2023
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2045-2059
Published Date: 4 August 2023
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:1677-1690
Published Date: 28 June 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M
Psoriasis: Targets and Therapy 2023, 13:19-26
Published Date: 4 May 2023
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study
Matteo M, Battista T, Noto M, Picone V, Fabbrocini G, Ruggiero A, Genco L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:553-564
Published Date: 2 March 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536
Published Date: 27 February 2023
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:369-373
Published Date: 5 February 2023
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Ruggiero A, Martora F, Fabbrocini G, Villani A, Marasca C, Megna M, Fornaro L, Comune R, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2022, 15:2785-2793
Published Date: 19 December 2022
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2022, 15:1649-1658
Published Date: 16 August 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022
Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients’ Assessment
Ruggiero A, Megna M, Villani A, Comune R, Fabbrocini G, di Vico F
Clinical, Cosmetic and Investigational Dermatology 2022, 15:661-673
Published Date: 14 April 2022
The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
Napolitano M, Fabbrocini G, Ruggiero A, Marino V, Nocerino M, Patruno C
Drug Design, Development and Therapy 2021, 15:1135-1147
Published Date: 10 March 2021